NCT02398461 - An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

September 21, 2017

Conditions

Multiple Sclerosis, Acute Relapsing

Interventions

DRUG

rHIgM22

Administered via IV infusion

DRUG

Placebo

Trial Locations (12)

Acorda Site #10, Rochester

Acorda Site #22, Chicago

Acorda Site #14, St Louis

Acorda Site #11, Aurora

Acorda Site #16, Centennial

Acorda Site #12, Long Beach

Acorda Site #7, San Francisco

Acorda Site #3, Sacramento

Acorda Site #2, Seattle

Acorda Site #6, Seattle

Acorda Site #19, Teaneck

Acorda Site #18, Dallas